March 24, 2022 — Zug, Switzerland — The Longevity Science Foundation, dedicated to advancing the healthy human lifespan, has created a new board to advise it on issues beyond longevity. These inaugural members hail from the worlds of cryptocurrency, blockchain and Big Data.

“Predictive diagnostics, therapeutics, personalized medicine and AI all play huge roles in extending the human lifespan,” the LSF visionary board chairman Evelyne Yehudit Bischof said. “But we are charting new territory and need to avail ourselves of the expertise of those from other sectors who have been making tremendous strides in their own spaces.”

The experts forming the Patrons Board include:

  • Maja Vujinovic, a trailblazer in tokenization that disrupts current business models. She runs OGroup, an investment and consulting firm, and sits on the board of CoinDesk. 
  • Valery Vavilov, founder, chief vision officer and chairman of the Bitfury Group, a company he founded in 2011 when blockchain technology was just starting to catch on.

The foundation also welcomes new advisors to its team: 

  • Lauren Berkowitz, an AI and biotech leader focused on emerging technologies. She is chief commercial officer for Bessor Pharma and a former executive at companies including IBM, Elemental Cognition and Bridgewater Associates. 
  • Anastasia Drinevskaya, creative director of Cointelegraph / chief executive officer of Cointelegraph Communications, a leading crypto media outlet. 
  • George Givishvili, chief executive officer of VBET Ukraine, an online betting platform. 

Press contact

Rachel Pipan, +31 06 422 13615, 

About the Longevity Science Foundation

The Longevity Science Foundation is a nonprofit organization advancing human longevity by funding research and development of medical technologies aimed at extending the healthy human lifespan. The long-term mission of the Longevity Science Foundation is to help make longevity-focused care accessible to everyone, no matter their background, by bringing cutting-edge science on ageing out of the laboratory and into the mainstream. To learn more, visit the site.